Biomedical researchers have engineered a chimeric nanoparticle platform designed to dismantle the structural scaffold of mycobacterial biofilms and reactivate innate immune defenses against persistent pulmonary infections. Investigating the composition of extracellular matrix barriers formed by Mycobacterium tuberculosis, the team discovered that non-canonical, left-handed Z-form deoxyribonucleic acid accumulates prominently alongside standard B-form architecture in mature biofilms and patient-derived specimens. Because this alternative helical structure resists conventional enzymatic degradation by standard deoxyribonuclease, the dense matrix protects resident bacilli from pharmaceutical penetration and cellular clearance. To overcome this biophysical defense, the investigators formulated a multi-component nanostructure designated Nano-NucleOTAC, which anchors specifically to extracellular nucleic acid scaffolds, converts the resistant left-handed geometry into a vulnerable conformation, and mediates comprehensive enzymatic cleavage across laboratory strains and clinical isolates.
Bacterial biofilms represent complex microbial communities encased within a protective matrix composed of extracellular polymeric substances, encompassing extracellular DNA, proteins, lipids, and polysaccharides. In tuberculosis pathogenesis, Mycobacterium tuberculosis establishes dense biofilm communities within human pulmonary granulomas, creating protected niches that drive clinical persistence, prolonged antibiotic regimens, and post-treatment resurgence. While bovine pancreatic deoxyribonuclease I has regulatory clearance as an agent to hydrolyze extracellular nucleic acids within bacterial matrices, its practical utility remains strictly constrained by inadequate matrix penetration and a pronounced inability to digest the steric conformation of left-handed Z-DNA. The study documented that as mycobacterial biofilms mature over time, Z-DNA steadily accumulates within the extracellular polymeric network, forming a sterically hindered scaffold that shields trapped bacilli from host phagocytes and conventional antimicrobial therapy.
News Source: Ophelia Keating. (November 16, 2026). Engineered Nanoparticles Disrupt Tuberculosis Biofilms and Stimulate Innate Antibacterial Immune Responses. Scienmag.